Primary sclerosing cholangitis (PSC) is a severe liver disease of unknown etiology leading to
fibrotic destruction of the bile ducts and ultimately to the need for liver transplantation 1 , 2 , …

In addition to the HLA locus, six genetic risk factors for primary biliary cirrhosis (PBC) have
been identified in recent genome-wide association studies (GWAS). To identify additional loci, …

The biochemical response to ursodeoxycholic acid (UDCA)—so‐called “treatment response”—strongly
predicts long‐term outcome in primary biliary cholangitis (PBC). Several long‐…

BACKGROUND, & AIMS: Studies of primary biliary cirrhosis (PBC) phenotypes largely have
been performed using small and selected populations. Study size has precluded …

Primary sclerosing cholangitis (PSC) is a rare progressive disorder leading to bile duct
destruction; ∼75% of patients have comorbid inflammatory bowel disease (IBD). We undertook …

Primary biliary cirrhosis (PBC) is a classical autoimmune liver disease for which effective
immunomodulatory therapy is lacking. Here we perform meta-analyses of discovery data sets …

We genotyped 2,861 cases of primary biliary cirrhosis (PBC) from the UK PBC Consortium
and 8,514 UK population controls across 196,524 variants within 186 known autoimmune risk …

Primary biliary cirrhosis (PBC) has a complex clinical phenotype, with debate about the extent
and specificity of frequently described systemic symptoms such as fatigue. The aim of this …

Background Treatment guidelines recommend a stepwise approach to primary biliary cholangitis:
all patients begin treatment with ursodeoxycholic acid (UDCA) monotherapy and those …

Backgrounds & Aims Primary biliary cholangitis (PBC) is a chronic liver disease in which
autoimmune destruction of the small intrahepatic bile ducts eventually leads to cirrhosis. Many …